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Background:Bacillus Calmette-Guérin (BCG) vaccination possesses effects on health beyond its target disease, the
so called “non-speciﬁc effects”. We evaluate these effects, as well as the effect of timing of BCG and other vacci-
nations, on stunting in Sub-Saharan African (SSA) children under ﬁve.
Methods:Weuse a Big Data design, including cross-sectional data for 368,450 children from33 SSA countries. Lo-
gistic regression analysis is used with control factors at child, mother, household and context level.
Results:Overall, BCG vaccination did not affect stunting in SSA children (OR 1.00 [0.98–1.03]). Timing of BCG vac-
cination was of importance (βtime = 0.067 [0.061–0.073]): compared to unvaccinated children, BCG was associ-
ated with lower odds on stunting for children vaccinated early in life (OR 0.92 [0.89–0.94]) and higher odds for
children vaccinated later in infancy (OR 1.64 [1.53–1.76]). Similarﬁndingswere done for diphtheria-tetanus-per-
tussis (DTP)1 and measles vaccination, and when hemoglobin concentration was used as outcome variable.
Conclusions:We found a general time-dependent pattern of non-speciﬁc effects of vaccination, with positive as-
sociations for vaccinations given early in life and negative associations for vaccinations given later in infancy. If
conﬁrmed in further research, our ﬁndings may provide a new perspective on the non-speciﬁc effects of
vaccination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Live attenuated vaccines, such as Bacillus Calmette-Guérin (BCG),
possess beneﬁcial non-speciﬁc effects outside the scope of their target
disease that have been associated with lower mortality rates (WHO,
2014a; Nankabirwa et al., 2015; Garly et al., 2003; Aaby et al., 2011).
Vaccinationwith BCG increases immune responses and protects against
unrelated pathogens (Kleinnijenhuis et al., 2012, 2014; Jensen et al.,
2015; Clark et al., 1976), possibly through a combination of trained im-
munity, induced by epigenetic reprogramming of innate immune cells
(Kleinnijenhuis et al., 2012), and heterologous T-helper (Th)1/Th17 im-
munity (Kleinnijenhuis et al., 2014). These general immunemodulatory
and antimicrobial effects of BCG may also affect stunting. Stunting re-
ﬂects failure to reach linear growth potential in the early years of life
and has a highly multifactorial etiology that includes nutritional factors,
infectious diseases, and socio-economic factors (reviewed in
Prendergast and Humphrey, 2014). Associations between several infec-
tious diseases and stunting have been established, whereby the most
profound effect is seen for diarrheal infections (Checkley et al., 2008).
In addition to wasting of nutrients, infection-related inﬂammation
could lead to stunting through down-regulation of insulin-like growth
factor 1 (IGF-1) expression (Prendergast et al., 2014).
Stunting affects approximately 165 million children under ﬁve,
many of whom live in Africa (36.5%) (Black et al., 2013) where stunting
rates in many areas are over 40% (Global Data Lab, 2016). Besides being
associatedwith an increasedmortality, stunting has negative long-term
effects on cognitive and psychosocial development (Crookston et al.,
2011), school performance (Martorell et al., 2010), and economic pro-
ductivity (Hoddinott et al., 2008). It is therefore an important outcome
to establish the total impact of non-speciﬁc effects of vaccination on
health status. Recently, the World Health Organization (WHO) has
made a 40% reduction of stunting in children under ﬁve before 2025 a
global target, underlining its importance (WHO, 2014b).
The beneﬁcial non-speciﬁc effects of BCG suggest that this vaccine
may be used to reduce stunting in low- and middle-income countries.
If BCG vaccination indeed reduces stunting, there would be substantial
potential for improvement, as coverage of BCG vaccination has stalled
at 77–85% in Africa since 2009 (WHO, 2014c). Apart from vaccination
coverage, timing of vaccination may be important, as the child's im-
mune function changes with age (Kollmann et al., 2012) and early im-
munization had stronger consequences related to non-speciﬁc effects
in one study (Aaby et al., 2011). This is important knowing that timing
of vaccinations still differs widely between and within low- and mid-
dle-income countries (Clark and Sanderson, 2009).
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We aim to study the overall effect of BCG and other vaccinations on
stunting, as well as the role of timing of vaccination, on a newly devel-
oped database including data on 368,450 children under ﬁve living in
33 Sub-Saharan African countries. Given the signiﬁcant variation in cov-
erage and timing of vaccination in the daily setting in Sub-Saharan Afri-
ca, our data make it possible to study the overall effect, as well as the
effect of the timing of vaccination in amuch broader setting than in ear-
lier research. To gain insight into the scope of our ﬁndings, we repeated
our analyses for other vaccinations (diphtheria-tetanus-pertussis [DTP]
and measles vaccine [MV]) and for another outcome (hemoglobin
concentration).
2. Methods
2.1. Study Population
This study used retrospective and cross-sectional data from the De-
mographic and Health Surveys (DHS). DHS household surveys have
been conducted in many low-income countries since the 1980s,
collecting demographic, health, and nutritional indicators (www.
dhsprogram.org). Each DHS consists of a household survey and separate
women's and men's surveys. In the women's survey, all usual resident
women aged 15 to 49 are invited for an oral interview which includes
a complete birth history with detailed questions, including retrospec-
tive vaccination and stunting information, on the children born in the
last ﬁve years. The team executing the DHS ensures protection of
human subjects in agreement with local and international laws.
A combined dataset was derived from the Database Developing
World (DDW, www.globaldatalab.org) that included all available DHS
(n = 76) for Sub-Saharan African countries (n = 33) between 1998
and 2014 that included BCG vaccination and height-for-age measure-
ment. Included were all children aged 1–60 months for whom valid in-
formation was available on stunting and BCG vaccination before age
12 months. Children aged one month or less were excluded, because
of the difﬁculty of differentiating between stunting and fetal growth
failure and of interpreting the effect of vaccination. The cut-off at
12months for BCG vaccinationwas based on the importance of children
being vaccinated before this point in life. There were 419,167 children
aged 1–60 months in the data, of whom 50,717 were excluded because
no information on stunting or BCG vaccination was available. The ﬁnal
study population, therefore, consisted of 368,450 children. To obtain na-
tional representative samples, the data were adjusted according to
weights provided by DHS. These weights were recoded to a mean of
one for all analyses performed, so that their application did not increase
the sample size.
2.2. Core Measures
BCG vaccination was retrieved from vaccination cards upon visit.
This was done for 183,476 of the 368,450 children (49.8%). For the
184,974 children (50.2%) of whom no card was available or vaccination
was not recorded, the mother was asked whether the child was vacci-
nated. Timing of vaccination was calculated by subtracting the date of
birth from the date of vaccination. The analysis of timing of vaccination
was restricted to 171,075 children (46.4%)with valid dates on a vaccina-
tion card.
To obtain information on stunting, length or heightwasmeasured in
centimeters to a precision of 1 decimal with a Shorr measuring board
following a standardized DHS protocol (ICF/DHS, 2012). The measure-
ment was voluntary and was not performed when the parent refused
or the child was too sick. The assignment of anthropometric z-scores
was performed by the DHS program (Rutstein and Rojas, 2006) based
on the WHO Child Growth Standards (WHO. Multicentre Growth
Reference Study Group, 2006). Children with scores ≤−2 were consid-
ered stunted.
We performed additional analyses using hemoglobin concentration
as outcome measure. This was measured in 47 of the 76 DHS surveys,
which resulted in a study population of 149,868 children aged 6–
60 months. This age range differs from that for stunting, since fetal he-
moglobin is usually replaced by adult hemoglobin at the age of
6 months. To measure hemoglobin concentration, the blood of the chil-
dren was obtained through a ﬁnger or heel prick. Consent to draw a
droplet of bloodwas asked after reading a consent statement to the par-
ent or responsible adult. Obtained blood was collected in a micro-cu-
vette and analyzed with a battery operated portable Hemocue
analyzer. Hemoglobin concentrationwasmeasured in g/dLwith a preci-
sion of 1 decimal (ICF/DHS, 2012). To exclude outliers and input errors,
the lowest and highest 0.1% of the hemoglobin concentrations were ex-
cluded from the analyses.
2.3. Important Covariates
We included covariates at the level of the child, the mother, the
household, and the context. Inclusion of covariates was based on litera-
ture, expert opinion and availability in DHS data. Child characteristics
included age (inmonths), sex, other vaccinations, birth order, preceding
birth interval, twin status (singleton or multiple birth), size at birth
(very small, smaller than average, average, larger than average, very
large), and vitamin A supplementation (Benn et al., 2010; Varela-Silva
et al., 2009). Age of the child was supplemented with age squared to
control for non-linearity in the relationship between age and stunting.
Characteristics of the mother were age (in years), height z-scores,
body mass index (BMI, in kg/m2), breastfeeding for 24 months, place
of delivery (home, public hospital, private hospital, other), education
(highest level), andmarital status (married or living together, widowed,
divorced or not living together) (Corsi et al., 2016). At the household
level, the place of residence (rural, urban) and household wealth were
included. Household wealth wasmeasured by the International Wealth
Index, a cross-nationally comparable index, running from 0 to 100,
based on the household's possession of consumer durables (TV, fridge,
car etc.), housing characteristics and access to basic services (Smits
and Steendijk, 2015). Geographical information regarding sub-national
district level was used to control for differences in context in which the
households were living. Within the 33 countries, 285 districts were dis-
tinguished. To addressmissing values in the covariates, the dummy var-
iable adjustment procedure was used (Allison, 2001). There were no
missing values in the core measures.
2.4. Statistical Analysis
To determine the effects of vaccination on stunting, logistic regres-
sion analysis was performed. For the analysis with hemoglobin concen-
trations as dependent variable, linear regression was used. All analyses
were controlled for the abovementioned covariates at the level of the
child, the mother, and the household. The analysis of timing of vaccina-
tion was performed for each vaccination separately, but included con-
trols for vaccination status with regard to the other vaccinations. To
control for variation in the context in which the children lived, a ﬁxed
effects design (Wooldridge, 2013) was used for all regression models,
whereby dummy variables for the 285 sub-national regions and for
the survey years were included. In this way, all (measured and unmea-
sured) context factors related to stunting at the regional level are con-
trolled for.
The effect of timing of BCG vaccination was studied with both a con-
tinuous and a categorical variable. The categorical time variable
consisted of the categories “before 1month”, “months 1–2.99”, “months
3–4.99”, “months 5–6.99”, “months 7–11.99”, “time unknown”, and
“not vaccinated” (reference). Because MV is usually given at 9 months
of age, therewere few cases ofMV in the early time frame.We therefore
increased the upper age limit for this analysis to 15 months and chose
the categories for MV as “before 6 months”, “months 6–7.99”, “months
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Fig. 1. Prevalence of BCG vaccination and stunting in 33 Sub-Saharan African countries. Geographical distribution for BCG vaccination coverage (a) and stunting (b) among children aged
1–60 months in Sub-Saharan Africa. BDI: Burundi, BEN: Benin, BFA: Burkina Faso, CIV: Cote d'Ivoire, CMR: Cameroon, COD: Democratic Republic of Congo, COG: Congo, COM: Comoros,
ETH: Ethiopia, GAB: Gabon, GHA: Ghana, GIN: Guinea, KEN: Kenya, LBR: Liberia, LSO: Lesotho, MDG: Madagascar, MLI: Mali, MOZ: Mozambique, MWI: Malawi, NAM: Namibia, NER:
Niger, NGA: Nigeria, RWA: Rwanda, SEN: Senegal, SLE: Sierra Leone, STP: Sao Tome and Principe, SWZ: Swaziland, TCD: Chad, TGO: Togo, TZA: Tanzania, UGA: Uganda, ZMB: Zambia,
ZWE: Zimbabwe.
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8–9.99”, “months 10–11.99”, “months 12–14.99”, “time unknown”, and
“not vaccinated” (reference).
The independence of the BCG andDTP1 ﬁndingswas tested in sever-
al sensitivity analyses: by analyzing the effects of BCG for children who
had not received DTP1, by analyzing the effects of DTP1 for children
whohad not received BCG and by testing for interaction between the ef-
fects of early BCG and DTP1 vaccination.
All analyses were performed in SPSS Statistics V22.0 (IBM, NY, USA)
and P = 0.05 was taken as a threshold for signiﬁcance.
3. Results
Of the 368,450 children included, 287,552 (78.0%) had received vac-
cinationwith BCG and 151,332 children (41.1%) had a length- or height-
for-age z-score (LAZ/HAZ) of two standard deviations below themedian
and were classiﬁed as being stunted. Both BCG coverage and stunting
levels differed widely across the 33 Sub-Saharan countries (Fig. 1a, b
and Supplementary Table 1). Baseline characteristics of children and
mothers are present in Supplementary Tables 2 and 3.
In the group vaccinated with BCG, 113,786 (39.6%) of the children
was stunted, compared to 37,548 (46.4%) in the unvaccinated group,
resulting in a crude odds ratio (OR) of 0.76 [95% CI: 0.74–0.77] in
favor of BCG vaccination. After correction for relevant child, maternal,
social-economic, and context factors the association with BCG vaccina-
tion disappeared (OR 1.00 [0.98–1.03]) (Supplementary Table 4).
3.1. Timing of Vaccination
There was a clear time-dependency of the association between BCG
vaccination and stunting within the ﬁrst year of life (βtime = 0.067
[0.061–0.073]). As expected, we found children who received a BCG
vaccination early in life to be less stunted than children without BCG
vaccination. However, rather unexpected, we found children who re-
ceived the BCG vaccination later in infancy to bemore stunted than chil-
dren without BCG vaccination (Fig. 2). The association shifted from a
reducedoddson stunting to an increased odds on stunting at 1.5months
(Fig. 3a). Broken down into relevant time periods, vaccinationwith BCG
was associated with a lower odds on stunting when given before
1 month of age (OR 0.92 [0.89–0.94]). In contrast, vaccination with
BCG was associated with increased odds on stunting when given be-
tween 1–2.99, 3–4.99 or 5–6.99 months of age (ORs 1.05 [1.01–1.09],
1.17 [1.11–1.23] and 1.25 [1.16–1.34], respectively) and with the
highest odds on stunting when given after 7 months of age (OR 1.64
[1.53–1.76]) (Fig. 3b). There was no indication of selection with respect
to the childrenwithout vaccination cards, as this group had a coefﬁcient
similar to the group with vaccination cards (ORdifference 0.995 [0.977–
1.013]). Repeating the analyses using HAZ as outcome measure instead
of the dichotomous stunting variable, resulted in a similar time-depen-
dent association (Supplementary Fig. 1).
3.2. Other Vaccinations
To explore whether the ﬁndings were restricted to BCG vaccination,
or reﬂect a more general timing effect of vaccination, we examined the
effects of other vaccinations in our data.
For DTP1, a similar time-dependent patternwas observed as for BCG
(βtime = 0.069 [0.063–0.076]), although the shift from a reduced odds
to an increased odds on stunting occurred somewhat later at 4.3months
(Fig. 3c). This time-dependent association was also seen with HAZ as
outcome measure (Supplementary Fig. 1). Broken down into the same
time periods as BCG, the association between DTP1 and stunting
showedmany similarities to the BCG pattern. DTP1 vaccination was as-
sociated with the lowest odds on stunting when given before 1 month
of age (OR 0.73 [0.68–0.77]). Vaccinations with DTP1 given later in in-
fancy were associated with an increased odds on stunting (ORs of 1.09
[1.03–1.16] and 1.32 [1.24–1.41] between 5–6.99 months and after
7 months of age, respectively) (Fig. 3d).
For MV vaccination we found a time-dependent association as well
(βtime= 0.050 [0.043–0.057]) that shifted from a reduced odds to an in-
creased odds on stunting at 10.7 months (Fig. 3e). Again, the time-de-
pendent association could be reproduced using HAZ as outcome
measure (Supplementary Fig. 1). However, as this vaccine is scheduled
later in life, the number of children who received this vaccination in the
early months of life was small, making a direct comparison with BCG
and DTP1 difﬁcult. Nevertheless, the same tendency was seen with the
lowest odds on stunting in the earliest category (b6 months OR 0.78
[0.71–0.82]) and the highest odds on stunting in the latest category (N-
12 months OR 1.13 [1.08–1.19]) (Fig. 3f).
Since children who receive a BCG vaccination often receive DTP1
vaccination as well, the time-dependent association might be caused
by only one of the vaccinations. We therefore analyzed the association
between BCG and stunting for children who had not received DTP1
and the association between DTP1 and stunting for children who had
not received BCG. These sensitivity analyses displayed the same time-
dependency of the association, showing the robustness of the ﬁndings
(Supplementary Fig. 2 and Supplementary Tables 5 and 6). When
Fig. 2. Relation between stunting and age for different categories of timing of BCG vaccination. The non-linearity of the relation between percentage of stunted children and age is shown
with a leveling of the percentage of stunted children aroundmonth 15. Compared to BCG unvaccinated children, lower percentages of stunted children are seen for early BCG vaccination,
while higher percentages of stunted children are seen for late BCG vaccination.
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studying the timing associations of BCG and DTP1 vaccinations simulta-
neously, the coefﬁcientsweremildly attenuated. However, the time-de-
pendency remained clearly visible (Supplementary Fig. 3 and
Supplementary Tables 7 and 8). Moreover, we performed an interaction
analysis to ﬁnd out whether combining early vaccination with BCG and
DTP1 would either strengthen or attenuate their separate associations.
This interaction analysis revealed a similar association as the additive
model without an interaction term (β −0.268 vs. −0.268) (Supple-
mentary Tables 7 and 9).
3.3. Hemoglobin Concentration
Subsequently, we tested the time associations on the child's hemo-
globin concentration, anothermarker thatmirrors the overall wellbeing
of the child and is also inﬂuenced by infections and inﬂammation
(Weiss and Goodnough, 2005). Knowing that this marker is more re-
versible than stunting, it provides the opportunity to study prolonged
effects of vaccination. Consistently, a similar association and time pat-
tern of BCG vaccination as for stunting was found for hemoglobin
concentration (βtime =−0.017 [−0.024–0.011]) (Fig. 4a). Association
with a higher hemoglobin concentration was seen for vaccination be-
fore 1 month of age (β = 0.079 [0.045–0.112]), while vaccination
given more than 7 months after birth tended to be associated with a
lower hemoglobin concentration (β = −0.074 [−0.151–0.004]).
DTP1 as well as MV showed similar results for hemoglobin concentra-
tion, with decreasing concentrations upon delayed vaccination (DTP1
βtime = −0.017 [−0.024–0.009]; MV βtime = −0.014 [−0.021–
0.007]) (Fig. 4b, c).
4. Discussion
In this study we found evidence that the timing of BCG vaccination
within the ﬁrst year of life might be important in determining the size
and direction of its non-speciﬁc effects on stunting and hemoglobin
concentration. Early vaccination reduced the odds on stunting (OR
0.92 [0.89–0.94]), while vaccination later in infancy increased the
odds on stunting (OR 1.64 [1.53–1.76]), compared to unvaccinated chil-
dren. The positive associations of early vaccination, as well as the
Fig. 3. Time-dependent effects of vaccination on stunting. Time-dependency of vaccination with BCG (a and b), DTP1 (c and d) and MV (e and f) is shown for odds on stunting in Sub-
Saharan African children aged 1–60 months. Timing as continuous variable showed a positive relation to odds on stunting for all vaccines (a, c and e) with shifts from reduced odds
ratios to increased odds rations at 1.5 months (BCG), 4.3 months (DTP1) and 10.7 months (MV) compared to unvaccinated children for the speciﬁed vaccine as indicated by the
dashed vertical lines. Broken down into relevant time periods the same trend is visible (b, d and f). *P b 0.05, ***P b 0.001 compared to unvaccinated children. A 2 log scale is used for
the ordinates in a, c and e.
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negative associations of vaccination later in infancy were also seen for
hemoglobin concentration. Similar patterns were observed for vaccina-
tion with DTP1 and MV.
Our results are in line with prior studies that examined the role of
vaccines on child morbidity and mortality. Vaccination with BCG,
which is given early in the EPI schedule (WHO, 2015), is associated
with reduced child mortality (WHO, 2014a; Nankabirwa et al., 2015;
Garly et al., 2003; Aaby et al., 2011). DTP vaccinations are generally
not associated with such an effect and may even be deleterious
(WHO, 2014a). Our study indicates that this may be related to the
timing of vaccination. This ﬁnding is supported by studies that show
detrimental effects of DTP vaccination when given after or in combina-
tion with MV (late vaccination) (Aaby et al., 2003, 2007), while beneﬁ-
cial effects are reported for early DTP vaccination (Vaugelade et al.,
2004; Lehmann et al., 2005). Similar to our ﬁndings, combining BCG
and DTP1 vaccination was reported to be the most beneﬁcial in several
studies (Aaby et al., 2015a; Hirve et al., 2012). In case ofMV, vaccination
at 4–8 months was also associated with lower child mortality than vac-
cination at 9–11months (Aaby et al., 2015b). Regarding childmorbidity,
BCG vaccination inﬂuenced acute lower respiratory tract infections
(ALRI) in a time-dependent manner, in a study by Hollm-Delgado et
al. (2014). However, while these authors ascribed this effect to concur-
rentDTP administration, our present data suggest that the timingof BCG
vaccination itself is crucial.
An underlying mechanism for the time-dependent association of
both BCG and DTP1 vaccination could lie in the different functional sta-
tus of the neonatal and child immune system. The neonatal immune
system has an anti-inﬂammatory proﬁle mirroring that of the mother
during pregnancy, while the child immune system shifts to a more
pro-inﬂammatory proﬁle, increasingly reﬂecting that of adults
(reviewed in Kollmann et al., 2012). It may be hypothesized that
when vaccines are given early in life, induction of both speciﬁc and
non-speciﬁc effects results in a more balanced immune reactivity,
while when vaccines are given later they trigger a stronger pro-
inﬂammatory response upon encountering a pathogen. On the other
hand, unvaccinated neonatesmay be less able to copewith repeated in-
fections after environmental exposure, leading to prolonged inﬂamma-
tion. As inﬂammation is associated with down regulation of the
expression of growth hormone (GH)/IGF-1, prolonged or increased in-
ﬂammation negatively inﬂuences linear growth, as well as erythropoie-
sis (Prendergast et al., 2014; Boyer et al., 1992). This would explain the
beneﬁts seen for stunting and hemoglobin concentration in children
vaccinated early, but not late, in life compared to unvaccinated children,
although this hypothesis requires experimental and clinical conﬁrma-
tion in future studies.
We used a Big Data design, including information on 368,450African
children showingmuchmore variation in timing of vaccination and liv-
ing situation than children in high-income countries. In this way we
were able to study effects of timing of vaccination in a much broader
perspective than has been possible in earlier research. The smaller ob-
servational studies that are usually done, lack the power and variation
in timing necessary to detect these effects, while advancing or postpon-
ing vaccination in clinical trials might be deemed unethical.
Limitations of the study lie within its observational character. Al-
thoughwe controlled for confounding on several levels, it cannot be ex-
cluded that residual confounding is present. For example, it cannot be
precluded that part of our results are due to variation in maternal com-
petency. Mothers that have their children vaccinated tend to be better
mothers and caretakers for their children. This is indeed visible in the
factors we controlled for during analysis (Supplementary Table 3).
Proxy variables regarding the child's health show that early vaccinated
children received more other vaccinations and vitamin A, were more
often delivered in a hospital and had higher educatedmothers than un-
vaccinated children. However, this does not hold for all proxy variables,
since unvaccinated children were most often breastfed, an important
nutritional factor. Moreover, maternal competency does not explain
why children who are vaccinated later in infancy do worse than unvac-
cinated children, as also the late vaccinated children outperformed
Fig. 4. Time-dependent effects of vaccination on hemoglobin concentrations. Time-dependency of vaccination with BCG (a), DTP1 (b) and MV (c) is shown for alterations in hemoglobin
concentrations in Sub-Saharan African children aged 6–60 months. Timing as continuous variable showed a negative relation to hemoglobin concentrations for all vaccines (a, b and c)
with shifts from improved concentrations to decreased concentrations at 4.5 months (BCG), 4.8 months (DTP1) and 11.4 months (MV) compared to unvaccinated children for the
speciﬁed vaccine as indicated by the dashed vertical lines.
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unvaccinated children on the abovementioned factors. The worse
situation for children vaccinated later in infancy can neither be ex-
plained by more distant proxies. BMI of the mother and the position
of the child in the family are better for late vaccinated children. This
makes maternal competency as an explanation less likely. Given that
the factors mentioned in Supplementary Table 3 were all used as
control factors in our models, it does not seem likely that our results
are inﬂuenced by the differences described here. However, it cannot
be ruled out completely that our results have been inﬂuenced by
other aspects of maternal competency which were not available in
our data.
A second limitation is the incompleteness of survey data. The time-
dependency of the non-speciﬁc effect of BCG vaccination is based on
vaccination dates of only 46.4% of the children. Our results do not sug-
gest differences between the groups with and without vaccination
dates (OR 0.995 [0.977–1.013]). However, non-random missing of vac-
cination dates among the different timing of vaccination groups could
potentially inﬂuence the results. For example, we observed that the
child's median age increased over the timing of vaccination groups
and that vaccination data for older childrenwere less likely to have orig-
inated from a card. These observations indicate that groups with a later
timing of vaccination have relatively more missing dates of BCG vacci-
nation. However, the households of older children where a vaccination
card was available are probably the better organized households. Fur-
thermore, the data covers only living children, which given the high
child mortality rates in Sub-Saharan Africameans that the ones who re-
ceived their vaccinations at a later time are on average a stronger pop-
ulation. In both cases, the impact of non-random missing would be
expected to have led to an attenuation rather than an aggravation of
the timing effect.
Other possible disturbing factors include differences in acquisition of
the outcome measures and inter-regional variations. Differences in ac-
quisition have been minimized by the use of objective ascertainment
of vaccination dates (vaccination cards) and height measurements and
the fact that during collection of the data, collectors were not aware of
any study that was going to be conducted with the outcomes. Inter-re-
gional variation was addressed by including ﬁxed-effects dummies at
the level of 285 sub-national areas, which effectively control for all
stunting-related risk factors that vary among these areas.
Although deﬁnitive causal relationships cannot be drawn from our
cross-sectional data, the uniformity of the ﬁndings across different vac-
cines and two outcomemeasures, the plausibility of the underlying hy-
pothesis, as well as the consistency with results of previous studies
suggests that the timing of vaccinations is important for their overall
health effects.
If conﬁrmed in further research, our ﬁndings may provide an inter-
esting new perspective on the non-speciﬁc effects of vaccination and
aid global efforts to reduce stunting and related negative health out-
comes. Firstly, with regard to stunting, it seems that full and early cov-
erage of vaccinations could substantially reduce stunting in low- and
middle-income countries. A simulation analysis (Supplementary Table
10 and accompanying text) indicates that if all children in this study
would have received BCG and DTP1 vaccination before 1 month of
age, a decrease in stunting of approximately 10% could be achieved. Sec-
ondly, improvement of timing of vaccinations may be reached with rel-
atively small and achievable adaptations to the existing vaccination
practice. Presently, multi-dose BCG vaccine vials are provided together
with the instructions that a certain minimal percentage of the dosages
should be administered, which limits health careworkers in vaccinating
small numbers of children (Hutchins et al., 1993). Using smaller multi-
dose or single dose vials could overcome this problem and in certain sit-
uations is even the most cost-effective option (Dhamodharan and
Proano, 2012). Lastly, the effects need not be limited to Africa, since
stunting is a major health problem in several other world regions with
suboptimal coverage and timing of vaccination, such as Latin America
and South Asia (Black et al., 2013; Clark and Sanderson, 2009).
Extending the interventions to these regions could further contribute
to the Global Target set by the WHO to reduce stunting with 40% by
2025.
5. Conclusion
In conclusion, our data indicate that timing of vaccinations plays a
role in determining the strength and direction of their non-speciﬁc ef-
fects on two important health indicators: linear growth andhemoglobin
concentration. If conﬁrmed in further epidemiological and immunolog-
ical research, these ﬁndingsmay shed a new light on the non-speciﬁc ef-
fects of vaccinations and may have consequences for vaccination
programs and schedules worldwide.
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